Autoimmune Diseases  >>  Cimzia (certolizumab pegol)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cimzia (certolizumab pegol) / Astellas, UCB
NCT00993668: Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Completed
4
224
US
Placebo, Certolizumab pegol, Cimzia®
UCB Pharma
Rheumatoid Arthritis
06/10
02/11
DoseFlex, NCT00580840 / 2007-005288-86: Dosing Flexibility Study in Patients With Rheumatoid Arthritis

Completed
4
333
Canada, US, Europe
Certolizumab pegol, CZP, Cimzia, Placebo
UCB Pharma
Rheumatoid Arthritis
12/10
03/11
NCT01147341: Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia

Checkmark P4 data: EULAR 2015
Jun 2015 - Jun 2015: P4 data: EULAR 2015
Checkmark Rheumatoid Arthritis
Jun 2014 - Jun 2014: Rheumatoid Arthritis
Completed
4
37
US
Cimzia, 1 ml liquid product containing 200mg of Certolizumab Pegol, Placebo, 1 ml Sodium Cloride 0.9%
Michael Schiff, MD, UCB Pharma
Rheumatoid Arthritis
01/12
01/12
PREDICT, NCT01255761: A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

Checkmark ACR/ARHP 2013
Sep 2013 - Sep 2013: ACR/ARHP 2013
Completed
4
736
US
Certolizumab Pegol (CZP), Cimzia
UCB Pharma
Rheumatoid Arthritis
10/12
12/12
SPEED, NCT01443364 / 2011-000385-35: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis

Completed
4
132
Europe
Certolizumab pegol, CIMZIA, CZP
UCB Italy s.p.a.
Rheumatoid Arthritis
05/15
05/15
SWITCH, NCT01295151 / 2010-023880-17: Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.

Checkmark P4 data - ACR/ARHP 2012 (SWITCH-RA)
Sep 2012 - Sep 2012: P4 data - ACR/ARHP 2012 (SWITCH-RA)
Completed
4
122
Europe
Etanercept, Abatacept, Rituximab, Adalimumab, Certolizumab Pegol, Infliximab, Golimumab
Julia Brown
Rheumatoid Arthritis
11/15
11/15
NCT01500278 / 2011-002067-20: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Checkmark From Exxelerate trial for moderate to severe rheumatoid arthritis
Mar 2017 - Mar 2017: From Exxelerate trial for moderate to severe rheumatoid arthritis
Hourglass Feb 2016 - Dec 2016 : From EXXELERATE trial for rheumatoid arthritis
Checkmark Head to head trial vs. Humira
Nov 2016 - Nov 2016: Head to head trial vs. Humira
Completed
4
915
Canada, US, Europe, RoW
Certolizumab Pegol (CZP), Cimzia, CZP, Adalimumab (ADA), Humira, ADA, Methotrexate (MTX), MTX
UCB Pharma SA, Parexel
Rheumatoid Arthritis
11/15
01/16

Download Options